Last Updated: November 16, 2026

Details for Patent: 6,433,003

« Back to Dashboard


Summary for Patent: 6,433,003
Title:Method for treating hyperhidrosis in mammals
Abstract:This invention is directed to methods for treating hyperhidrosis in mammals. Specifically, the methods of this invention involve the topical administration of glycopyrrolate compounds to humans.
Inventor(s):Arthur M. Bobrove, Jeffrey D. Urman
Assignee: Rose U LLC
Application Number:US09/552,011
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

United States Patent 6,433,003: Scope, Claim Construction, Expiration, and Hyperhidrosis Patent Landscape

US Patent 6,433,003 covers methods of treating hyperhidrosis with topical or pharmaceutical compositions containing glycopyrrolate compounds at concentrations from approximately 0.25% to 6% by weight. The broadest practical protection is directed to treating an identified hyperhidrosis patient with a glycopyrrolate composition, rather than to a particular brand, formulation excipient, device, or manufacturing process. The patent term has expired, so US 6,433,003 no longer creates an enforceable US exclusion right.

What does US Patent 6,433,003 cover?

The patent covers glycopyrrolate-based treatment of excessive sweating, including facial, neck, and palmar hyperhidrosis. Its claims contain four principal limitations:

Claim element Scope
Disease or condition Hyperhidrosis
Patient A mammal, narrowed to a human in claims 2-4 and 6-8
Active ingredient A glycopyrrolate compound, including pharmaceutically acceptable salts
Concentration Approximately 0.25% to 6% by weight; claim 8 narrows this to 0.5% to 4.0%
Administration Topical administration in claim 1; claim 6 states administration of a pharmaceutical composition without expressly repeating "topically"
Treatment result Hyperhidrosis must be "substantially reduced"

The patent is a method-of-treatment patent. It does not claim glycopyrrolate as a chemical compound, glycopyrrolate generally as an anticholinergic, or every possible hyperhidrosis formulation independent of concentration and use.

How should the independent claims be construed?

Claim 1: topical treatment of hyperhidrosis

Claim 1 requires:

  1. Identifying a mammal susceptible to hyperhidrosis;
  2. Topically administering a composition to the skin;
  3. Using approximately 0.25% to 6% by weight of a glycopyrrolate compound; and
  4. Achieving a substantial reduction in hyperhidrosis.

This claim is broad as to the affected body site, formulation excipients, dosing frequency, application schedule, and specific glycopyrrolate salt. Claims 3 and 4 separately identify facial/neck and palmar use, but those limitations do not appear in claim 1.

A product would fall within the literal scope of claim 1 if its labeled or actual use involved topical treatment of hyperhidrosis with glycopyrrolate in the claimed concentration range. The claim does not require a prescription product, a particular container, a specific dosage volume, or a particular clinical scoring system.

Claim 6: pharmaceutical composition administered to a human

Claim 6 covers a human method using a pharmaceutical composition containing 0.25% to approximately 6% glycopyrrolate and a pharmaceutically acceptable excipient.

The claim does not expressly state "topically." That creates a potentially broader textual scope than claim 1. The specification, claim context, and prosecution history would control whether a court interprets claim 6 as limited to topical administration. A literal reading could reach routes beyond dermal delivery, but the patent's disclosed invention is centered on topical treatment of hyperhidrosis. Claim construction would therefore be material in any infringement dispute.

Claims 5 and 7: glycopyrrolate salt limitation

Claims 5 and 7 require a compound having the patent's Formula I, with X- defined as a pharmaceutically acceptable counterion. These claims narrow the glycopyrrolate definition to the disclosed formula and acceptable salt forms.

The salt limitation can matter commercially. Glycopyrronium tosylate, glycopyrrolate bromide, and other salt forms may present different infringement and equivalence questions depending on the exact formula, claim language, prosecution history, and product composition. A salt is not automatically outside the patent merely because it differs from a named example.

What is the claim-by-claim scope of US 6,433,003?

Claim Type Principal limitation Commercial significance
1 Independent method Topical treatment of mammalian hyperhidrosis with 0.25%-6% glycopyrrolate Broadest express topical claim
2 Dependent Human patient Removes nonhuman mammal scope
3 Dependent Face and neck application Targets craniofacial hyperhidrosis
4 Dependent Palm application Targets palmar hyperhidrosis
5 Dependent Formula I glycopyrrolate salt Narrows active ingredient identity
6 Independent method Human treatment with 0.25%-6% glycopyrrolate plus excipient Broad pharmaceutical-composition claim; route requires construction
7 Dependent Formula I compound under claim 6 Narrows claim 6 to the disclosed salt structure
8 Dependent 0.5%-4.0% concentration Covers a commercially practical concentration range

The claims do not expressly require:

  • A particular excipient in claim 1;
  • A particular solvent or vehicle;
  • A cream, gel, lotion, wipe, pad, spray, foam, or aerosol;
  • A specific treatment frequency;
  • A specific duration of treatment;
  • A particular level of sweat reduction;
  • Combination treatment with aluminum chloride, botulinum toxin, iontophoresis, or another therapy;
  • A particular glycopyrrolate salt in claim 1 or claim 6.

What concentrations are protected?

The concentration ranges are central to infringement analysis.

Range Relevant claim
Approximately 0.25%-6.0% Claims 1 and 6
0.5%-4.0% Claim 8
Below 0.25% Outside the literal concentration range, subject to equivalents analysis
Above 6.0% Outside the literal concentration range, subject to equivalents analysis

The use of "about" in claims 1 and 6 introduces tolerance around the endpoints. The scope cannot be determined solely by arithmetic. Courts would examine intrinsic evidence, including the specification, examples, prosecution amendments, and any arguments made to distinguish prior art.

Claim 8 is narrower than claims 1 and 6. A product at 0.5% to 4.0% may satisfy both the broad independent claim and claim 8, assuming the remaining limitations are met. A product at 0.3% would potentially fall within claims 1 and 6 but not claim 8.

What formulations are protected by US 6,433,003?

The patent can reach multiple topical dosage forms if they contain the claimed glycopyrrolate concentration and are used to reduce hyperhidrosis. Potentially relevant forms include:

  • Creams;
  • Gels;
  • Lotions;
  • Solutions;
  • Suspensions;
  • Ointments;
  • Topical wipes;
  • Foams;
  • Sprays;
  • Transdermal or dermal delivery systems.

Claim 6 expressly requires a pharmaceutically acceptable excipient. Claim 1, as supplied, does not expressly impose that limitation. A commercially marketed product would ordinarily contain excipients, but the difference may affect claim interpretation and validity analysis.

The patent does not appear, from the supplied claims, to require:

  • A water-based vehicle;
  • Alcohol;
  • A preservative;
  • A penetration enhancer;
  • A particular pH;
  • A specific viscosity;
  • A sealed wipe substrate;
  • A unit-dose package;
  • A low-systemic-absorption profile.

Later patents directed to specific salts, vehicles, packaging systems, delivery devices, stability profiles, or dosing regimens can create separate blocking rights even when US 6,433,003 has expired.

When did US 6,433,003 lose exclusivity?

US 6,433,003 was issued on August 13, 2002. Its US patent term was based on the applicable 20-year term measured from the relevant nonprovisional filing or international filing date, subject to patent-term adjustment and any terminal disclaimer. Public patent records identify the patent as expired after its statutory term. The patent therefore does not presently block generic, compounded, or branded topical glycopyrrolate products in the United States. [1]

The expiration of US 6,433,003 does not eliminate later patent risk. A later product may still be covered by patents directed to:

  • Glycopyrronium tosylate;
  • Specific topical compositions;
  • Wipes or delivery devices;
  • Dosing regimens;
  • Stability or packaging;
  • Treatment of particular body regions;
  • Manufacturing processes;
  • Combination therapy.

What is the Orange Book status of US 6,433,003?

US 6,433,003 is not the controlling Orange Book patent for current glycopyrronium products. Orange Book-listed patents are product-specific and must be assessed against the applicable NDA, dosage form, strength, and approved labeling. The patent number alone does not establish Orange Book listing status.

Qbrexza, a glycopyrronium tosylate topical cloth, was approved by the FDA in 2018 for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. Its product-specific patent estate is separate from US 6,433,003. [2, 3]

Sofdra, a sofpironium topical gel, received FDA approval in 2024 for primary axillary hyperhidrosis in adults and pediatric patients 12 years of age and older. It has a different active ingredient and a separate patent portfolio. [4]

Which products are commercially relevant to this patent landscape?

Product or therapy Active ingredient or modality FDA status Relationship to US 6,433,003
Qbrexza Glycopyrronium tosylate 2.4% topical cloth FDA-approved in 2018 Technically close to the patent's topical glycopyrrolate concept, but later product patents control current risk
Sofdra Sofpironium topical gel FDA-approved in 2024 Different active ingredient; generally outside glycopyrrolate claims
Compounded topical glycopyrrolate Glycopyrrolate salt or base, variable concentration Generally compounded rather than FDA-approved as a finished hyperhidrosis product May have implicated the expired claims historically; current US 6,433,003 risk is extinguished by expiration
Drysol and similar products Aluminum chloride FDA-regulated topical antiperspirant products Different active ingredient and claim pathway
Botulinum toxin therapy Botulinum toxin type A FDA-approved for selected hyperhidrosis use Different modality
Iontophoresis Electrical delivery of water or medication Device-based treatment Different modality

Qbrexza is the closest commercial comparator because it uses a topical glycopyrronium salt at 2.4%, within the concentration range stated in US 6,433,003. That technical overlap does not mean the older patent is the primary current barrier. The relevant analysis now shifts to Qbrexza-specific patents, regulatory exclusivity, Orange Book listings, and any later patents covering glycopyrronium tosylate delivery.

What was the patent strength of US 6,433,003?

Strengths at filing and during its term

The patent had several commercially important features:

  • Broad concentration range;
  • Coverage of topical administration;
  • Coverage of multiple body sites;
  • Coverage of mammalian and human treatment;
  • Salt flexibility through the glycopyrrolate compound and Formula I limitations;
  • No requirement for a particular vehicle in claim 1;
  • Claims directed to a therapeutic use rather than a narrow product configuration.

Those features could have made the patent relevant to compounded preparations and early branded topical glycopyrrolate products.

Limitations

The estate also had limitations:

  • It did not claim glycopyrrolate as a composition of matter;
  • It did not claim every antiperspirant treatment;
  • It required a specified concentration range;
  • It required treatment of hyperhidrosis and substantial reduction;
  • Claim 6 presents route-of-administration ambiguity;
  • Later products could pursue distinct claims around salts, delivery systems, wipes, dosing, stability, and packaging;
  • Expiration eliminates current injunctive and damages exposure for post-expiration conduct.

The expired status is now more commercially important than the original breadth. The patent has historical relevance but no current blocking value in the United States.

Were there Paragraph IV challenges or settlements involving this patent?

A Paragraph IV certification must be evaluated against the patents listed for a specific FDA-approved reference product. US 6,433,003 is not, by itself, a current Qbrexza or Sofdra patent strategy. A generic applicant would ordinarily direct a Paragraph IV challenge at patents listed for the relevant reference listed drug, not at an expired, non-listed patent.

The supplied claim set does not establish a Paragraph IV filing, ANDA litigation, or settlement involving US 6,433,003. Any current challenge involving Qbrexza or Sofdra must be analyzed separately through the FDA Orange Book, district court complaints, docket entries, and settlement filings. [2, 5]

Are biosimilar risks relevant?

No. Biosimilar law does not apply to a small-molecule glycopyrrolate product. The relevant competitors are ANDA applicants, 505(b)(2) applicants, compounding pharmacies, branded topical products, and non-drug devices.

Sofdra is not a biosimilar or generic equivalent to Qbrexza. It contains sofpironium, a different active ingredient, and competes through a separate NDA and patent estate.

What geographic coverage does US 6,433,003 provide?

US 6,433,003 provides only US patent rights. It does not directly control products sold in Canada, Europe, Japan, or other jurisdictions. Foreign counterparts must be analyzed independently for:

  • Filing date;
  • National-phase status;
  • Patent-term adjustment or supplementary protection;
  • Claim scope;
  • Opposition or revocation history;
  • Expiration;
  • Local regulatory linkage.

An expired US patent can coexist with live foreign counterpart patents, although the international family must be reviewed on a jurisdiction-by-jurisdiction basis.

Key Takeaways

  • US 6,433,003 claims methods of treating hyperhidrosis with glycopyrrolate compositions at approximately 0.25% to 6% by weight.
  • Claim 1 is the principal topical treatment claim.
  • Claims 3 and 4 target facial/neck and palmar application.
  • Claim 6 may be broader in wording because it does not expressly repeat the topical route.
  • Claim 8 narrows the concentration to 0.5%-4.0%.
  • The patent is a method-of-use patent, not a composition-of-matter patent.
  • The patent has expired and does not presently block US commercialization.
  • Qbrexza is the closest commercial product because it uses 2.4% glycopyrronium tosylate in a topical cloth.
  • Qbrexza and Sofdra depend on separate, later patent and regulatory estates.
  • Paragraph IV analysis must focus on patents listed for the applicable reference product.
  • Biosimilar law is not relevant because glycopyrrolate and sofpironium are small-molecule products.
  • Current freedom-to-operate analysis should focus on later formulation, delivery, salt, dosing, manufacturing, Orange Book, and regulatory-exclusivity rights.

FAQs

Does US 6,433,003 cover Qbrexza?

Technically, Qbrexza's 2.4% topical glycopyrronium tosylate product is close to the concentration and topical-use concepts in the patent. US 6,433,003 has expired, so it does not currently block Qbrexza or a competing product.

Is a 2% topical glycopyrrolate product within the claimed range?

Yes. A 2% product falls within the 0.25%-6% range of claims 1 and 6 and within the 0.5%-4.0% range of claim 8, subject to the other claim limitations.

Is a 0.1% glycopyrrolate preparation covered?

A 0.1% preparation is below the stated lower endpoint. It would not literally satisfy the numerical range, although historical infringement analysis could have required an equivalents assessment. The patent is expired.

Does the patent cover oral glycopyrrolate for hyperhidrosis?

Claim 6 does not expressly state a route, but claim construction would depend on the specification and prosecution history. Claim 1 expressly requires topical administration. The expired status makes the issue commercially immaterial for current US exclusion rights.

Can a company market a topical glycopyrrolate product without a license to the patent owner?

US 6,433,003 itself is expired, so no current license is required for that patent. A launch may still implicate later unexpired patents, FDA requirements, state pharmacy rules, product-specific Orange Book patents, and trademark rights.

References

  1. United States Patent and Trademark Office. (2002). U.S. Patent No. 6,433,003, Treatment of hyperhidrosis.
  2. U.S. Food and Drug Administration. (2018). Qbrexza approval letter and prescribing information.
  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  4. U.S. Food and Drug Administration. (2024). Sofdra approval letter and prescribing information.
  5. U.S. Food and Drug Administration. (2024). Patent and exclusivity information resources for approved drug products.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 6,433,003

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.